香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 請參閱百濟神州有限公司（「百濟神州」或「本公司」）於2023年6月16日和2025年4 月30日就Pharmacyclics LLC（「Pharmacyclics」）發起的專利侵權指控發佈的公告。 本公司宣佈，Pharmacyclics決定不對美國專利商標局的最終書面決定提起上 訴，該最終書面決定宣布Pharmacyclics在專利授權後複審程序中受到百濟神 州質疑的第11,672,803號美國專利（「'803專利」）的全部權利無效。百濟神州和 Pharmacyclics於2025年9月30日（美國時間）向相關地方法院提交一份共同協議， 自願撤回訴訟案件，案件已做出終局處理。 承董事會命 百濟神州有限公司 主席 歐雷強先生 香港，2025年10月2日 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 於本公告日期，本公司董事會包括主席兼執 ...

Market Sector - The Sci-Tech Innovation Board (STAR Market) index increased by 51.20% in the first three quarters of 2025, ranking second among various sector indices, outperforming the North Exchange 50, Shenzhen 50, and Shanghai 50 indices [2] - As of the end of Q3 2025, the total market capitalization of the STAR Market reached 10.95 trillion yuan, an increase of 3.33 trillion yuan from 7.62 trillion yuan at the end of Q2 2025, representing a growth rate of 43.66%, which is higher than other sectors [4] - The total trading volume of the STAR Market reached 25.93 trillion yuan in the first three quarters of 2025, with an average trading volume of 440.32 billion yuan per stock, which is lower than the average trading volumes of stocks in the Shanghai and Shenzhen main boards and the ChiNext [6] - The average daily turnover rate of the STAR Market was 2.99% in the first three quarters of 2025, higher than that of the Shanghai main board but lower than that of the Shenzhen main board, ChiNext, and North Exchange [8] - The price-to-book ratio of the STAR Market was 5.78 times at the end of Q3 2025, higher than that of the ChiNext and Shanghai and Shenzhen main boards [11] - The financing balance of the STAR Market reached 244.335 billion yuan at the end of Q3 2025, an increase of 99.034 billion yuan from 145.301 billion yuan at the beginning of the year [13] - The margin trading balance of the STAR Market was 0.829 billion yuan at the end of Q3 2025, an increase of 0.037 billion yuan from 0.459 billion yuan at the beginning of the year [15] Individual Stocks - As of the end of Q3 2025, SMIC led with a market capitalization exceeding 700 billion yuan, followed by Haiguang Information, Cambricon Technologies, and BeiGene, with 11 companies having market capitalizations exceeding 100 billion yuan [18] Industry Themes - In the first three quarters of 2025, companies listed on the STAR Market were primarily distributed across three Wind Sci-Tech theme industries, with the new generation information technology industry leading with four companies, followed by high-end equipment manufacturing and biotechnology industries, each with one company [29] - Among the seven companies issued on the STAR Market in the first three quarters of 2025, six were listed under Standard One, which requires positive net profits for the last two years and a cumulative net profit of no less than 50 million yuan, or a positive net profit for the last year with operating income of no less than 100 million yuan, and an expected market capitalization of no less than 1 billion yuan [31] - The companies issued on the STAR Market in the first three quarters of 2025 came from Beijing and Jiangsu (two each), and Hubei, Zhejiang, and Guangdong (one each) [34] - The total IPO financing on the STAR Market in the first three quarters of 2025 was 7.901 billion yuan, a year-on-year decrease of 9.99%, with three companies raising over 1 billion yuan, three raising between 500 million to 1 billion yuan, and one raising less than 500 million yuan [36] - Yitang Co., Ltd. led the IPO financing in the first three quarters of 2025 with 2.497 billion yuan, while Yingshi Innovation and Xingfu Electronics each raised over 1 billion yuan [40]

Market Overview - The Hang Seng Index (HSI) closed at 26,751.60, down by 103.96 points or 0.39% as of September 30, 16:00 Eastern Time [1] - The index reached a high of 26,811.89 and a low of 26,663.28 during the trading session, with an average price of 26,737.59 [1] - The 52-week high for the index is 26,915.35, while the 52-week low is 18,856.77, indicating a trading range of 0.55% for the day [1] Blue-Chip Stocks Performance - Major blue-chip stocks mostly declined, with HSBC Holdings closing at HKD 110.477, up by 0.98% compared to the Hong Kong close [2] - Tencent Holdings closed at HKD 662.66, down by 0.05% compared to the Hong Kong close [2] Individual Stock Movements - Tencent Holdings (00700) saw a price increase of HKD 3.00, or 0.45%, with an ADR price of HKD 662.660, which is a decrease of HKD 0.340 compared to its Hong Kong price [3] - Alibaba Group (09988) increased by HKD 3.60, or 2.08%, with an ADR price of HKD 173.866, down HKD 3.134 from its Hong Kong price [3] - HSBC Holdings (00005) rose by HKD 0.60, or 0.55%, with an ADR price of HKD 110.477, up HKD 1.077 from its Hong Kong price [3] - Other notable movements include Kuaishou (01024) increasing by HKD 5.70, or 7.22%, and BYD Company (01211) rising by HKD 1.60, or 1.47% [3]

Market Performance - The Hong Kong stock market indices experienced significant gains, with the Hang Seng Tech Index rising by 2.24%, reaching a new high for the period [1] - In September, the Hang Seng Tech Index accumulated a nearly 14% increase, while the Hang Seng Index and the National Enterprises Index rose by 7.09% and 6.79%, respectively [1][2] Sector Highlights - Major technology stocks saw collective gains, with Kuaishou leading with a rise of over 7%, followed by Alibaba and NetEase with increases of 2% [2][4] - Semiconductor stocks remained strong, with Huahong Semiconductor surging nearly 11% to set a new high [2][8] - Apple-related stocks also saw gains as Apple reportedly notified its supply chain to increase production capacity [2][9] Gold and Copper Stocks - Gold stocks rallied, with Zijin Mining International soaring over 68%, and other gold-related companies also showing strong performance [6] - Copper stocks followed suit, with China Molybdenum rising by 11.84% and Jiangxi Copper gaining over 8% [7] Biopharmaceutical Sector - The biopharmaceutical sector showed positive movement, with WuXi AppTec increasing by over 8% and other companies like Zai Lab and BeiGene also experiencing gains [12][13] Airline Industry - Airline stocks generally rose, with China Eastern Airlines up by 6.73% and both China Southern Airlines and Air China increasing by over 4% [11] - Citic Securities noted strong demand for air travel during the upcoming holidays, suggesting potential for positive performance in the sector [11] Oil and Gas Sector - Oil stocks collectively declined, with China Petroleum falling by 2.75% and other major oil companies also experiencing losses [14] - Reports indicated that OPEC+ plans to increase oil production in November, contributing to the downward pressure on oil prices [14] Gaming and Telecom Stocks - Casino and gaming stocks mostly fell, with Sands China down by 2.25% and other major gaming companies following suit [15] - Telecom stocks also saw declines, with China Telecom and China Mobile both experiencing slight drops [17] Capital Inflows - Southbound capital saw a net inflow of HKD 15.48 billion, indicating strong investor interest in the Hong Kong market [19] Future Outlook - Everbright Securities highlighted the strong overall profitability of Hong Kong stocks, particularly in sectors like internet, new consumption, and innovative pharmaceuticals, suggesting that despite recent gains, valuations remain low and long-term investment potential is high [19]

中邮证券研报指出，百济神州上半年实现归母净利润4.5亿元（去年同期为-28.8亿元）、25Q2实现归母 净利润5.4亿元（去年同期为-9.7亿元）。公司同时将全年收入指引从此前的49-53 亿美元上调至50-53亿 美元、全年GAAP经营利润为正的指引不变。25Q2 泽布替尼环比稳定增长，地舒单抗快速放量。公司 为创新药出海龙头企业，全球商业化能力突出、在研管线即将进入收获期，首次覆盖，给予"买入"评 级。 ...

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [2][9]. Core Insights - The company reported a significant increase in revenue and net profit for the first half of 2025, with total revenue reaching 17.52 billion yuan, a 46% increase year-on-year, and a net profit of 450 million yuan compared to a loss of 2.88 billion yuan in the same period last year [5][6]. - The company has raised its full-year revenue guidance from 4.9-5.3 billion USD to 5-5.3 billion USD, while maintaining its guidance for positive GAAP operating profit for the year [5][6]. Financial Performance - In Q2 2025, the company achieved a revenue of 9.47 billion yuan, a 42.7% increase year-on-year, and a net profit of 540 million yuan, compared to a loss of 970 million yuan in the same quarter last year [5][6]. - The global revenue for the drug Zebutinib reached 1.74 billion USD in the first half of 2025, with a year-on-year growth of 54.7%, driven by strong performance in the US and Europe [6][7]. Product Development - The company is advancing its product pipeline, with several key trials underway, including a Phase III trial for a combination therapy involving Zebutinib [7][8]. - The company anticipates significant data releases in the second half of 2025 for various products, including a KRAS inhibitor and ADCs [8]. Earnings Forecast - The company is projected to achieve revenues of 37.1 billion yuan, 47.15 billion yuan, and 58.18 billion yuan for the years 2025, 2026, and 2027, respectively, with corresponding net profits of 820 million yuan, 4.07 billion yuan, and 8.07 billion yuan [9][11].

Core Viewpoint - BeiGene's stock price has shown significant volatility and growth in 2023, with a notable increase in revenue and net profit for the first half of the year [2][3]. Stock Performance - As of September 30, BeiGene's stock rose by 2.02% to 307.09 CNY per share, with a trading volume of 5.59 billion CNY and a market capitalization of 473.13 billion CNY [1]. - Year-to-date, BeiGene's stock price has increased by 90.72%, with a 1.17% rise in the last five trading days, a 5.47% decline over the past 20 days, and a 37.62% increase over the last 60 days [2]. Financial Performance - For the period from January to June 2025, BeiGene reported a revenue of 17.518 billion CNY, representing a year-on-year growth of 46.03%, and a net profit attributable to shareholders of 450 million CNY, up 115.63% year-on-year [2]. Shareholder Information - As of June 30, 2025, the number of shareholders for BeiGene was 23,300, a decrease of 3.90% from the previous period, with an average of 4,976 circulating shares per shareholder, an increase of 4.11% [2]. - Among the top ten circulating shareholders, notable changes include an increase in holdings by China Europe Medical Health Mixed A and a decrease in holdings by Wan Jia You Xuan [3].

Core Conclusion - The investment logic for innovative drugs indicates that 2025 will mark a new recovery starting point for China's innovative drug industry after a deep adjustment, driven by a "triple resonance" of policy, industry, and capital [3][5][7]. Policy Insights - The Chinese government has explicitly supported innovative drugs in the 2025 Government Work Report, with subsequent policies aimed at high-quality development and commercial insurance for innovative drugs, clearing development obstacles across the entire chain [3][5]. Industry Dynamics - The internationalization process is accelerating, with the License-out model becoming a key path for value realization. In the first three quarters of 2025, upfront payments for licensing transactions reached $5.7 billion, surpassing the total for 2024 and accounting for 23.4% of the global total, indicating a significant enhancement in the global value chain position of Chinese innovative drug assets [5][7]. Capital Market Trends - After a deep adjustment from 2022 to 2024, industry valuations are returning to rational levels, with continuous improvement in the fundamentals of companies. In the first half of 2025, sales revenue from 17 commercialized innovative drug companies grew by 30% year-on-year, with leading companies like Innovent Biologics achieving profitability, marking a phase of value reassessment in the industry [7]. Market Size and Growth - The global innovative drug market is expected to reach $782.6 billion in 2024, accounting for 51.3% of the global pharmaceutical market, and is projected to grow to $1,119 billion by 2029, with a compound annual growth rate (CAGR) of 7.4%, outpacing the overall pharmaceutical market growth of 6.4% [14]. Industry Structure - The innovative drug industry chain is divided into three main segments: upstream (raw materials and support), midstream (R&D and production), and downstream (distribution and payment), forming a complete value chain from scientific discovery to market application [19][21][24]. Business Model Transformation - Chinese innovative drug companies are transitioning from a single reliance on domestic market sales to a dual-driven international strategy of "domestic sales + License-out," marking a new phase where product strength and business model innovation are equally emphasized [28][29]. Revenue Sources - The revenue sources for innovative drug companies are diversifying, including domestic insurance sales, License-out income, and overseas market sales. In 2023, insurance spending on innovative drugs reached 90 billion yuan, maintaining rapid growth since 2019 [28][29][34]. BD Model Growth - The BD (Business Development) model has become a core engine for commercialization, with the total amount of BD transactions involving Chinese innovative drug companies skyrocketing from $5.06 billion in 2020 to $41.76 billion by August 2025, indicating a fundamental shift in the industry's business model [37][38]. Key Segments to Watch - The innovative drug industry includes six key segments: small molecule drugs, large molecule drugs, cell therapy, gene therapy, mRNA vaccines, and precision medicine, each deserving in-depth research [43].

Market Overview - The Hang Seng Index (HSI) closed at 26,665.59, up by 42.71 points or 0.16% on September 29 [1] - The index reached a high of 26,699.71 and a low of 26,495.38 during the trading session, with a trading volume of 61.6389 million [1] - The 52-week high for the index is 26,915.35, while the 52-week low is 18,856.77, indicating a trading range of 0.77% [1] Major Blue-Chip Stocks Performance - HSBC Holdings closed at HKD 109.701, up 0.83% from the previous close [2] - Tencent Holdings closed at HKD 661.446, reflecting a 0.22% increase from the previous close [2] ADR and Stock Price Movements - Tencent Holdings (ADR) increased by 2.48% to HKD 660.000, with an ADR conversion price of HKD 661.446, showing a rise of HKD 1.446 compared to its Hong Kong stock price [3] - Alibaba Group (ADR) rose by 4.14% to HKD 173.400, with an ADR conversion price of HKD 175.032, indicating an increase of HKD 1.632 [3] - HSBC Holdings (ADR) saw a 1.97% increase to HKD 108.800, with an ADR conversion price of HKD 109.701, up by HKD 0.901 [3] - Other notable movements include a 2.66% increase for Trip.com Group and a 3.09% increase for JD.com [3]

Core Viewpoint - The potential imposition of a 100% tariff on imported brand and patented drugs by the Trump administration starting October 1, 2025, has raised concerns among pharmaceutical companies, particularly those in China, leading to a decline in their stock prices [2][3]. Group 1: Impact on Pharmaceutical Companies - The announcement of the tariff has caused significant declines in the stock prices of Chinese pharmaceutical companies, with Heng Rui Pharmaceutical dropping 3.03% in A-shares and 2.23% in Hong Kong shares, and BeiGene falling 4.38% in A-shares and 1.55% in Hong Kong shares [2]. - The Hang Seng Innovative Drug Index (HSIDI) fell by 2.37%, with notable declines in stocks such as Fosun Pharma, which dropped 5.82%, and 3SBio, which fell by 5.34% [3]. - Industry experts suggest that the impact of the tariff on Chinese pharmaceutical companies may be limited, as many are focused on generic drugs and active pharmaceutical ingredients (APIs) [4]. Group 2: Industry Perspectives - Some industry leaders believe that the tariff policy may not be implemented as proposed, citing the high cost of drugs in the U.S. and the potential for political changes in future administrations [4][5]. - Companies like Heng Rui Pharmaceutical indicated that their current exports primarily consist of generics and APIs, suggesting minimal impact from the proposed tariffs [4]. - Other companies, such as Lepu Biopharma, noted that their licensing partnerships would shield them from significant effects [5]. Group 3: U.S. Policy Context - The Trump administration has previously threatened to impose tariffs on imported drugs, with discussions around a 200% tariff and subsequent smaller tariffs leading to a potential increase over time [6][7]. - Major multinational pharmaceutical companies have responded to the tariff threats by committing to significant investments in U.S. manufacturing, with companies like Novartis and Roche pledging $23 billion and $50 billion respectively over the next five years [8].